Pancreatic Cancer Research

ResearcherSignablok, Inc.No recent work listed

Alexander B Sigalov

ORCID-verified (high confidence)As of 13 November 2026

Matched on ORCID iD 0000-0003-2118-1800; OpenAlex author ID A5016467167; NIH RePORTER profile ID 10750414.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers
1 (first author 0, last author 1)
Pancreatic cancer trials
0
Pancreatic cancer grants
3
Collaborators
1
Papers, trials and grants by year

2015: 1 grant · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 grant · 2020: 1 grant

Papers 1

  1. Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer. Last author DOI 10.1021/acs.molpharmaceut.7b00711↗

Grants 3

  1. First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer R44CA217400↗
  2. First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer R43CA217400↗
  3. Development of novel targeted agents in pancreatic cancer R43CA195684↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

  1. Zu T. Shen · 1 shared paper, 2017

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.